Response to letter commenting on published paper: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

Eur J Cancer. 2018 May:94:218-219. doi: 10.1016/j.ejca.2018.02.002. Epub 2018 Mar 13.

Authors

Larysa H M Rydzewska¹, Sarah Burdett², Claire L Vale², Mahesh K B Parmar², Jayne F Tierney²

Affiliations

¹ MRC Clinical Trials Unit at UCL, London, UK. Electronic address: [email protected].
² MRC Clinical Trials Unit at UCL, London, UK.

PMID: 29548532
DOI: 10.1016/j.ejca.2018.02.002

No abstract available

Publication types

Letter
Comment

MeSH terms

Androstenes*
Humans
Male
Prostatic Neoplasms*

Substances

Androstenes
abiraterone